Skip to main content
ARIX BIOSCIENCE PLC logo

ARIX BIOSCIENCE PLC — Investor Relations & Filings

Ticker · ARIX ISIN · GB00BD045071 LEI · 213800OVT3AHQCXNIX43 IL Financial and insurance activities
Open in API
Filings indexed 547 across all filing types
Latest filing 2023-05-05 Declaration of Voting R…
Country GB United Kingdom
Listing IL ARIX

About ARIX BIOSCIENCE PLC

https://www.arixbioscience.com/

Arix Bioscience plc is a global venture capital company that specializes in the biotechnology and life sciences sectors. The firm's primary activity involves investing in and building innovative biotech companies, providing capital and strategic support from early stages, including seed, preclinical, and clinical development. Arix focuses on identifying and nurturing breakthrough advances in life sciences to accelerate the development of new medical technologies and therapies. According to public information, the company has entered into a process of liquidation.

Recent filings

Filing Released Lang Actions
Total Voting Rights
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is identified by the 'RNS Number' header and explicitly states it is provided by 'RNS, the news service of the London Stock Exchange'. The content announces the 'Total Voting Rights' as of a specific date (May 4, 2023), detailing the total issued shares, treasury shares, and the resulting total voting rights (129,389,508). This type of announcement, which communicates a specific, periodic regulatory update regarding share capital structure and voting rights, fits best under the category related to voting rights or general regulatory announcements. Since there is a specific category for 'Declaration of Voting Results & Voting Rights Announcements' (DVA), this is the most precise fit, as it directly addresses the total voting rights figure used for shareholder notification calculations under the Disclosure Guidance and Transparency Rules. It is not a full AGM report (AGM-R) or a general regulatory filing (RNS), but a specific voting rights update.
2023-05-05 English
Director/PDMR Shareholding
Director's Dealing Classification · 1% confidence The document is identified by the 'RNS Number' header and explicitly mentions 'RNS, the news service of the London Stock Exchange'. The content details transactions (sale and purchase) of shares by a Person Discharging Managerial Responsibilities (PDMR), Robert Lyne, CEO of Arix Bioscience Plc. This type of insider transaction reporting, especially when mandated by regulations like the UK Market Abuse Regulation, falls under the category of Director's Dealing (DIRS). Although it is an RNS announcement, the specific content points directly to DIRS, which is a more precise classification than the general RNS fallback.
2023-05-04 English
Director/PDMR Shareholding
Director's Dealing Classification · 1% confidence The document is identified by the 'RNS Number' header and explicitly states it is provided by 'RNS, the news service of the London Stock Exchange'. The content details a transaction by a Person Discharging Managerial Responsibilities (PDMR), specifically a Non-Executive Director purchasing shares. This type of insider transaction disclosure falls directly under the definition of Director's Dealing (DIRS). Although it is an RNS filing, DIRS is the more specific and appropriate category for insider trade reports.
2023-05-04 English
Director/PDMR Shareholding
Director's Dealing Classification · 1% confidence The document is a notification released via RNS (London Stock Exchange news service) on May 2, 2023. The content explicitly details 'PDMR notifications & Director Shareholdings,' reporting transactions (purchases, option exercises, and sales to cover tax liabilities) made by Persons Discharging Managerial Responsibilities (PDMRs), including the CEO and Non-Executive Directors. This type of insider transaction reporting is specifically covered by the 'Director's Dealing' definition. Although it is distributed via RNS, the specific content points directly to DIRS rather than the general RNS fallback.
2023-05-02 English
Arix Co-leads $50 Million Series B Financing for New Portfolio Company Evommune
Share Issue/Capital Change Classification · 1% confidence The document announces that Arix Bioscience plc co-led a $50 Million Series B Financing for its portfolio company, Evommune. This is a specific announcement regarding a financing activity and capital investment in a portfolio company. This directly aligns with the definition of 'Capital/Financing Update' (CAP). Although it is a press release format, the core subject matter is financing, not a general regulatory update (RNS) or a report publication announcement (RPA). The length is moderate, but the content is specific enough to classify it beyond a general regulatory filing.
2023-04-27 English
Arix Bioscience Plc - Annual Report & Accounts to 31 December 2022 - ESEF
Annual Report (ESEF) Classification · 1% confidence FY 2022
2023-04-26 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.